Preclinical biotech developing pan-variant kinase inhibitors for solid tumors.
Industry: Health Care
Latest Trade: $4.06 0.00 (0.0%)
First Day Return: +16.1%
Return from IPO: -74.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/15/2021 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 10.0 |
Deal Size ($mm) | $160 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 10/06/2021 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 10.0 |
Deal Size ($mm) | $160 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Jefferies |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2017 |
Employees at IPO | 14 |
Website theseusrx.com |